Pharmena S.A.

As of June 30, 2026, Pharmena S.A. carries a market capitalization of 35.08M, placing it among publicly traded companies globally. Its enterprise value stands at 29.47M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, Pharmena S.A. has 11.14M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 24.01, and the price-to-book ratio stands at 4.29.

These figures are as of June 30, 2026. The EV/Sales ratio of 20.17 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 29.47M versus a market cap of 35.08M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Pharmena S.A. maintains a current ratio of 6.69, meaning it holds 6.7x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 3.84, indicating elevated leverage, while an interest coverage ratio of -138.91 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Pharmena S.A. posted a negative return on equity (ROE) of -31.51, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -28.15, reflecting losses generated across the asset base. The company generates approximately 81,166.67 in revenue per employee across its workforce of 18.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 0.36 indicates how many times Pharmena S.A. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Pharmena S.A. recorded 12,000.00 in income tax expense. The company reported a pretax loss of -3.04M and -3.06M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 22, 2026, Pharmena S.A.'s stock has declined approximately 11.28% over the past 52 weeks. The 50-day moving average sits at 3.11, while the 200-day moving average is 3.28.

Over the twelve months ended June 30, 2026, Pharmena S.A. generated 1.46M in revenue and converted that into -3.06M in net income, yielding earnings per share of -0.27. EBITDA reached -3.19M, while operating income came in at -3.33M.

As of June 30, 2026, Pharmena S.A. holds 5.93M in cash and equivalents against 314,000.00 in total debt, resulting in a net debt position of -421,000.00. Total book value stands at 8.17M, with working capital of 6.25M providing operational flexibility.

Pharmena S.A. produced -3.04M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -456,000.00 in capital expenditures, free cash flow totaled -3.49M - equivalent to -0.31 per share.

Over the twelve months ended June 30, 2026, Pharmena S.A. posted a gross margin of 82.27, reflecting its pricing power and cost economics. The operating margin of -227.99 and net profit margin of -209.24 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -9.96: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield reaches 0.34, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Pharmena S.A. shareholders.

Pharmena S.A.'s most recent stock split took place on December 19, 2018.

As of June 30, 2026, Pharmena S.A. has an Altman Z-Score of 14.07, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.